CoChat

Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells

Open access

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

Abstract

The array of genome editing strategies based on targeted double-stranded DNA break formation have recently been enriched through the introduction of transcription activator-like type III effector (TALE) nucleases (TALENs). To advance the testing of TALE-based approaches, it will be crucial to deliver these custom-designed proteins not only into transformed cell types but also into more relevant, chromosomally stable, primary cells. Viral vectors are among the most effective gene transfer vehicles. Here, we investigated the capacity of human immunodeficiency virus type 1- and adenovirus-based vectors to package and deliver functional TALEN genes into various human cell types. To this end, we attempted to assemble particles of these two vector classes, each encoding a monomer of a TALEN pair targeted to a bipartite sequence within the AAVS1 'safe harbor' locus. Vector DNA analyses revealed that adenoviral vectors transferred intact TALEN genes, whereas lentiviral vectors failed to do so, as shown by their heterogeneously sized proviruses in target cells. Importantly, adenoviral vector-mediated TALEN gene delivery resulted in site-specific double-stranded DNA break formation at the intended AAVS1 target site at similarly high levels in both transformed and non-transformed cells. In conclusion, we demonstrate that adenoviral, but not lentiviral, vectors constitute a valuable TALEN gene delivery platform.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/nar/gks1446

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Structural analyses of HIV-1-based lentiviral vectors harboring TALEN sequences in transduced cells. (A) Genetic organization of lentiviral vector constructs. Diagram of bicistronic pLV.TALEN-LS1.i.RFP and pLV.TALEN-RS1.i.RFP and of monocistronic pLV.TALEN-LS1 and pLV.TALEN-RS1 lentiviral vector transfer plasmids. The bicistronic constructs code for the AAVS1-specific custom-made nucleases TALEN-LS1 or TALEN-RS1 and, through an IRES sequence, an RFP reporter, whereas the monocistronic plasmids encode exclusively the AAVS1-specific designer nucleases. Each of the TALEN proteins are tagged by an HA antigen located close to their N-termini (not drawn). Gray boxes with broken arrow, hybrid 5′ LTR containing CMV and HIV-1 sequences; gray boxes without broken arrow, self-inactivating (SIN) 3′ LTR; Ψ, HIV-1 packaging signal; RRE, Rev-responsive element; cPPT, central polypurine tract; WPRE, Woodchuck hepatitis virus posttranscriptional regulatory element. In pLV.TALEN-LS1.i.RFP and pLV.TALEN-RS1.i.RFP, the ORFs are under the transcriptional control of the CMV promoter and the polyadenylation signal present within the SIN 3′ LTR, whereas the ORFs in pLV.TALEN-LS1 and pLV.TALEN-RS1 are under the control of the CMV promoter and the bovine growth hormone polyadenylation signal (bGH). Primers, PCR products and Southern blot probe used are depicted as half-arrows, black bars and gray bar, respectively, and are drawn in relation to their respective vector DNA sequences. For the sake of simplicity, plasmid backbone sequences are not shown. The sizes of the PCR products expected from the amplification of full-length lentiviral vector genomes are indicated. The 6.4-kb AflII restriction fragment corresponding to intact DNA from LV.TALEN-LS1 or LV.TALEN-RS1 is also indicated. (B) PCR analyses of TALEN-encoding HIV-1-based lentiviral vector genomes following transduction of HeLa cells. PCR amplifications with the aid of the primers shown in Figure 1A were carried out using, as template, total cellular DNA from mock-transduced HeLa cells, plasmid pAd.ΔE1.TALEN-LS1.F50, plasmid pLV.CMV.eGFP or nuclease-free H20 (lanes 1, 2, 3 and 4, respectively). PCR amplifications using the same primer pairs were performed in parallel on DNA extracted from HeLa cells transduced with integration-competent LV.TALEN-RS1 (lane 5), integrase-defective IDLV.TALEN-RS1 (lane 6), Ad.ΔE1.TALEN-RS1.F50 (lane 10) or integration-competent LV.TALEN-RS1.i.RFP (lane 11). Extra PCR controls supplementing those corresponding to lanes 1 through 4 were provided by using DNA isolated from HeLa cells exposed to an LV.TALEN-RS1 preparation made in parallel but deploying pUC19 instead of lentiviral vector packaging construct psPAX2 (lane 7) or incubated with pLV.TALEN-RS1 mixed or not mixed with the DNA transfection agent ExGen500 (lanes 8 and 9, respectively). Lanes M, Gene Ruler DNA Ladder Mix. A primer pair targeting the human HPRT1 served to control the integrity of the cellular DNA. (C) Clonal analysis. Southern blot analysis of AflII-digested genomic DNA from HeLa cell clones 1 through 15 stably transduced with LV.TALEN-LS1. The vector-specific probe that was used is shown in Figure 1A (horizontal gray bar). Lane M, 1 kb molecular-weight marker. The parental transfer plasmid pLV.TALEN-LS1 treated with AflII served as an internal control for intact vector DNA. (D) PCR screening of genomic DNA from HeLa cell clones stably transduced with LV.TALEN-LS1. Upper and lower panel, PCR products resulting from the use of the primer pairs CMV-prom.F/TALE.as.Pr2 and TAL-N.s/TAL-N.as, respectively, on HeLa cell clones 1 through 8 (note: clone 8 turned out to yield two closely sized and vector-specific amplicons, thus the nomenclature 8.1 and 8.2). PCR amplifications on plasmid pLV.TALEN-LS1 served as a positive control (+), whereas those on nuclease-free water (W) and HeLa genomic DNA (H) provided for negative controls. Lanes M, Gene Ruler DNA Ladder Mix. (E) Structural analyses of proviral vector DNA. DNA sequencing of amplicons retrieved from HeLa cell clones 2, 5, 6, 7 and 8 after PCR amplifications with primers CMV-prom.F and TALE.as.Pr2 (Figure 1D, upper panel). Upper panel, summary of the TALE repeat arrays present in the indicated LV.TALEN-LS1-transduced HeLa cell clones. The respective predicted target sites, lengths, size reduction in relation to the wild-type sequence and the number of 102-bp long TALE repeat units found to be deleted, are also indicated. Lower panel, alignment of the TALEN-LS1 DNA sequences retained in the various proviruses (horizontal thin lines) drawn in relation to the reference wild-type sequence (horizontal thick line). (F) TALEN protein detection. HA tag-directed western blot analysis of full-length TALEN-LS1 expression in 293T producer cells (lane 1), IDLV.TALEN-LS1- and LV.TALEN-LS1-transduced HeLa cells (lane 2 and lane 4, respectively) and in pLV.TALEN-LS1-transfected 293T cells used to generate these IDLV.TALEN-LS1 and LV.TALEN-LS1 vector preparations (lanes 3 and 5, respectively). Lane 6, HeLa cells transfected with pLV.TALEN-LS1. The β-actin served as loading control.
Figure 1. Structural analyses of HIV-1-based lentiviral vectors harboring TALEN sequences in transduced cells. (A) Genetic organization of lentiviral vector constructs. Diagram of bicistronic pLV.TALEN-LS1.i.RFP and pLV.TALEN-RS1.i.RFP and of monocistronic pLV.TALEN-LS1 and pLV.TALEN-RS1 lentiviral vector transfer plasmids. The bicistronic constructs code for the AAVS1-specific custom-made nucleases TALEN-LS1 or TALEN-RS1 and, through an IRES sequence, an RFP reporter, whereas the monocistronic plasmids encode exclusively the AAVS1-specific designer nucleases. Each of the TALEN proteins are tagged by an HA antigen located close to their N-termini (not drawn). Gray boxes with broken arrow, hybrid 5′ LTR containing CMV and HIV-1 sequences; gray boxes without broken arrow, self-inactivating (SIN) 3′ LTR; Ψ, HIV-1 packaging signal; RRE, Rev-responsive element; cPPT, central polypurine tract; WPRE, Woodchuck hepatitis virus posttranscriptional regulatory element. In pLV.TALEN-LS1.i.RFP and pLV.TALEN-RS1.i.RFP, the ORFs are under the transcriptional control of the CMV promoter and the polyadenylation signal present within the SIN 3′ LTR, whereas the ORFs in pLV.TALEN-LS1 and pLV.TALEN-RS1 are under the control of the CMV promoter and the bovine growth hormone polyadenylation signal (bGH). Primers, PCR products and Southern blot probe used are depicted as half-arrows, black bars and gray bar, respectively, and are drawn in relation to their respective vector DNA sequences. For the sake of simplicity, plasmid backbone sequences are not shown. The sizes of the PCR products expected from the amplification of full-length lentiviral vector genomes are indicated. The 6.4-kb AflII restriction fragment corresponding to intact DNA from LV.TALEN-LS1 or LV.TALEN-RS1 is also indicated. (B) PCR analyses of TALEN-encoding HIV-1-based lentiviral vector genomes following transduction of HeLa cells. PCR amplifications with the aid of the primers shown in Figure 1A were carried out using, as template, total cellular DNA from mock-transduced HeLa cells, plasmid pAd.ΔE1.TALEN-LS1.F50, plasmid pLV.CMV.eGFP or nuclease-free H20 (lanes 1, 2, 3 and 4, respectively). PCR amplifications using the same primer pairs were performed in parallel on DNA extracted from HeLa cells transduced with integration-competent LV.TALEN-RS1 (lane 5), integrase-defective IDLV.TALEN-RS1 (lane 6), Ad.ΔE1.TALEN-RS1.F50 (lane 10) or integration-competent LV.TALEN-RS1.i.RFP (lane 11). Extra PCR controls supplementing those corresponding to lanes 1 through 4 were provided by using DNA isolated from HeLa cells exposed to an LV.TALEN-RS1 preparation made in parallel but deploying pUC19 instead of lentiviral vector packaging construct psPAX2 (lane 7) or incubated with pLV.TALEN-RS1 mixed or not mixed with the DNA transfection agent ExGen500 (lanes 8 and 9, respectively). Lanes M, Gene Ruler DNA Ladder Mix. A primer pair targeting the human HPRT1 served to control the integrity of the cellular DNA. (C) Clonal analysis. Southern blot analysis of AflII-digested genomic DNA from HeLa cell clones 1 through 15 stably transduced with LV.TALEN-LS1. The vector-specific probe that was used is shown in Figure 1A (horizontal gray bar). Lane M, 1 kb molecular-weight marker. The parental transfer plasmid pLV.TALEN-LS1 treated with AflII served as an internal control for intact vector DNA. (D) PCR screening of genomic DNA from HeLa cell clones stably transduced with LV.TALEN-LS1. Upper and lower panel, PCR products resulting from the use of the primer pairs CMV-prom.F/TALE.as.Pr2 and TAL-N.s/TAL-N.as, respectively, on HeLa cell clones 1 through 8 (note: clone 8 turned out to yield two closely sized and vector-specific amplicons, thus the nomenclature 8.1 and 8.2). PCR amplifications on plasmid pLV.TALEN-LS1 served as a positive control (+), whereas those on nuclease-free water (W) and HeLa genomic DNA (H) provided for negative controls. Lanes M, Gene Ruler DNA Ladder Mix. (E) Structural analyses of proviral vector DNA. DNA sequencing of amplicons retrieved from HeLa cell clones 2, 5, 6, 7 and 8 after PCR amplifications with primers CMV-prom.F and TALE.as.Pr2 (Figure 1D, upper panel). Upper panel, summary of the TALE repeat arrays present in the indicated LV.TALEN-LS1-transduced HeLa cell clones. The respective predicted target sites, lengths, size reduction in relation to the wild-type sequence and the number of 102-bp long TALE repeat units found to be deleted, are also indicated. Lower panel, alignment of the TALEN-LS1 DNA sequences retained in the various proviruses (horizontal thin lines) drawn in relation to the reference wild-type sequence (horizontal thick line). (F) TALEN protein detection. HA tag-directed western blot analysis of full-length TALEN-LS1 expression in 293T producer cells (lane 1), IDLV.TALEN-LS1- and LV.TALEN-LS1-transduced HeLa cells (lane 2 and lane 4, respectively) and in pLV.TALEN-LS1-transfected 293T cells used to generate these IDLV.TALEN-LS1 and LV.TALEN-LS1 vector preparations (lanes 3 and 5, respectively). Lane 6, HeLa cells transfected with pLV.TALEN-LS1. The β-actin served as loading control.CC BY-NC · PubMed Central
Figure 2. Structural analysis of TALEN-encoding adenoviral vector genomes. (A) DNA structures of the first-generation adenoviral vectors Ad.ΔE1.TALEN-LS1.F50 and Ad.ΔE1.TALEN-RS1.F50 and of the second-generation adenoviral vectors Ad.ΔE1ΔE2A.TALEN-LS1.F50 and Ad.ΔE1ΔE2A.TALEN-RS1.F50 drawn in relation to those of their respective plasmid clones. The adenoviral vector and shuttle plasmid DNA templates are depicted as BcuI physical maps with numerals specifying the different restriction fragment sizes in kilobases (kb). These DNA molecules harbor a bi-cistronic expression unit coding for the AAVS1-specific artificial nucleases TALEN-LS1 or TALEN-RS1 and, through an IRES sequence, an RFP reporter. The ORFs are under the transcriptional control of the cytomegalovirus immediate-early gene promoter (CMV) and the simian virus 40 (SV40) polyadenylation signal. The central regions of TALEN-LS1 and TALEN-RS1 encode a tandem of 17.5 TALE repeats that define specificity to the AAVS1 target sequence at the human chromosome 19 (19q13.42-qter). C-terminally both TALENs contain the non-specific cleavage domain of FokI, whose catalytic activity is contingent on DNA binding-dependent dimerization. Each of the TALEN proteins are tagged by an HA antigen located close to their N-termini (not drawn). The thick and thin lines represent adenoviral vector and plasmid backbone sequences, respectively. Ψ, human adenovirus serotype 5 packaging signal; Ad L-ITR and Ad R-ITR, ‘left’ and ‘right’, respectively, adenoviral inverted terminal repeat. F50, ORF encoding chimeric fiber composed of basal shaft domains from adenovirus serotype 5 fused to apical shaft and knob motifs from adenovirus serotype 50. The kanamycin-resistance gene (KanR) and the prokaryotic origin of replication (ori) are also indicated. (B) Restriction fragment length analysis of Ad.ΔE1.TALEN-LS1.F50 and Ad.ΔE1.TALEN-RS1.F50 genomes treated with BcuI. Plasmids pAd.ΔE1.TALEN-LS1.F50 and pAd.ΔE1.TALEN-RS1.F50 served as a reference. The sizes (in kb) of the DNA restriction fragments resulting from the BcuI treatment are indicated on the left. The arrowhead points to the 2.4-kb DNA fragments diagnostic for intact, non-rearranged, TALE-derived DNA sequences within TALEN-encoding genes. Marker, molecular-weight marker Gene Ruler DNA Ladder Mix. (C) PCR analysis on DNA isolated from Ad.ΔE1.TALEN-LS1.F50 and Ad.ΔE1.TALEN-RS1.F50 particles using primers TALEN-Seq-F and TALEN-Seq-R (F and R half arrows, respectively). These primers, drawn in relation to their respective target sequences, amplify most of the TALEN-LS1 and TALEN-RS1 DNA including the 17 102-bp tandem DNA repeats. The position (arrowheads) and size (in kb) of the 2.1-kb amplicon diagnostic for intact TALEN transgenes are indicated at the right. Marker, Gene Ruler DNA Ladder Mix. H20, PCR performed with nuclease-free water instead of vector DNA template. (D) Autoradiogram of MunI-treated extrachromosomal DNA isolated from HeLa cells transduced with Ad.ΔE1.TALEN-LS1.F50 or with Ad.ΔE1.TALEN-RS1.F50 at MOIs of 10, 5 and 1 HTU/cell. The DNA, extracted at 3 days post-transduction, was subjected to Southern blot analysis using a 397-bp probe hybridizing to a sequence encoding the NH2 terminus of the TALEN-LS1 and TALEN-RS1 proteins.
Figure 2. Structural analysis of TALEN-encoding adenoviral vector genomes. (A) DNA structures of the first-generation adenoviral vectors Ad.ΔE1.TALEN-LS1.F50 and Ad.ΔE1.TALEN-RS1.F50 and of the second-generation adenoviral vectors Ad.ΔE1ΔE2A.TALEN-LS1.F50 and Ad.ΔE1ΔE2A.TALEN-RS1.F50 drawn in relation to those of their respective plasmid clones. The adenoviral vector and shuttle plasmid DNA templates are depicted as BcuI physical maps with numerals specifying the different restriction fragment sizes in kilobases (kb). These DNA molecules harbor a bi-cistronic expression unit coding for the AAVS1-specific artificial nucleases TALEN-LS1 or TALEN-RS1 and, through an IRES sequence, an RFP reporter. The ORFs are under the transcriptional control of the cytomegalovirus immediate-early gene promoter (CMV) and the simian virus 40 (SV40) polyadenylation signal. The central regions of TALEN-LS1 and TALEN-RS1 encode a tandem of 17.5 TALE repeats that define specificity to the AAVS1 target sequence at the human chromosome 19 (19q13.42-qter). C-terminally both TALENs contain the non-specific cleavage domain of FokI, whose catalytic activity is contingent on DNA binding-dependent dimerization. Each of the TALEN proteins are tagged by an HA antigen located close to their N-termini (not drawn). The thick and thin lines represent adenoviral vector and plasmid backbone sequences, respectively. Ψ, human adenovirus serotype 5 packaging signal; Ad L-ITR and Ad R-ITR, ‘left’ and ‘right’, respectively, adenoviral inverted terminal repeat. F50, ORF encoding chimeric fiber composed of basal shaft domains from adenovirus serotype 5 fused to apical shaft and knob motifs from adenovirus serotype 50. The kanamycin-resistance gene (KanR) and the prokaryotic origin of replication (ori) are also indicated. (B) Restriction fragment length analysis of Ad.ΔE1.TALEN-LS1.F50 and Ad.ΔE1.TALEN-RS1.F50 genomes treated with BcuI. Plasmids pAd.ΔE1.TALEN-LS1.F50 and pAd.ΔE1.TALEN-RS1.F50 served as a reference. The sizes (in kb) of the DNA restriction fragments resulting from the BcuI treatment are indicated on the left. The arrowhead points to the 2.4-kb DNA fragments diagnostic for intact, non-rearranged, TALE-derived DNA sequences within TALEN-encoding genes. Marker, molecular-weight marker Gene Ruler DNA Ladder Mix. (C) PCR analysis on DNA isolated from Ad.ΔE1.TALEN-LS1.F50 and Ad.ΔE1.TALEN-RS1.F50 particles using primers TALEN-Seq-F and TALEN-Seq-R (F and R half arrows, respectively). These primers, drawn in relation to their respective target sequences, amplify most of the TALEN-LS1 and TALEN-RS1 DNA including the 17 102-bp tandem DNA repeats. The position (arrowheads) and size (in kb) of the 2.1-kb amplicon diagnostic for intact TALEN transgenes are indicated at the right. Marker, Gene Ruler DNA Ladder Mix. H20, PCR performed with nuclease-free water instead of vector DNA template. (D) Autoradiogram of MunI-treated extrachromosomal DNA isolated from HeLa cells transduced with Ad.ΔE1.TALEN-LS1.F50 or with Ad.ΔE1.TALEN-RS1.F50 at MOIs of 10, 5 and 1 HTU/cell. The DNA, extracted at 3 days post-transduction, was subjected to Southern blot analysis using a 397-bp probe hybridizing to a sequence encoding the NH2 terminus of the TALEN-LS1 and TALEN-RS1 proteins.CC BY-NC · PubMed Central
Figure 3. Adenoviral vector-mediated delivery of TALEN genes into transformed and non-transformed human cells. (A) Gene transfer efficiency. Upper panel, phase-contrast and live-cell RFP direct fluorescence microscopy on HeLa cells transduced with Ad.ΔE1.TALEN-LS1.F50 or with Ad.ΔE1.TALEN-RS1.F50 at an MOI of 6 HTU/cell or with a mixture of the two adenoviral vectors at an MOI of 6 HTU/cell each. Lower panel, RFP direct fluorescence microscopy on immortalized DMD myoblasts and on primary hMSCs transduced with Ad.ΔE1.TALEN-LS1.F50 or with Ad.ΔE1.TALEN-RS1.F50 at an MOI of 12 HTU/cell or co-transduced with a 1:1 mixture of Ad.ΔE1.TALEN-LS1.F50 and Ad.ΔE1.TALEN-RS1.F50 at a total MOI of 24 HTU/cell. The fluorescence microscopy images were acquired at 48 h post-infection. (B) HA tag-specific immunofluorescence microscopy on HeLa cells mock-transduced or transduced with Ad.ΔE1.TALEN-LS1.F50 or with Ad.ΔE1.TALEN-RS1.F50 at an MOI of 3 HTU/cell. The direct fluorescence microscopy and the immunofluorescence microscopy were carried out at 48 and 72 h post-infection, respectively. (C) HA tag-directed western blot analysis of protein lysates derived from HeLa cell cultures incubated for 72 h with Ad.ΔE1.TALEN-LS1.F50 or with Ad.ΔE1.TALEN-RS1.F50. The MOIs deployed are indicated.
Figure 3. Adenoviral vector-mediated delivery of TALEN genes into transformed and non-transformed human cells. (A) Gene transfer efficiency. Upper panel, phase-contrast and live-cell RFP direct fluorescence microscopy on HeLa cells transduced with Ad.ΔE1.TALEN-LS1.F50 or with Ad.ΔE1.TALEN-RS1.F50 at an MOI of 6 HTU/cell or with a mixture of the two adenoviral vectors at an MOI of 6 HTU/cell each. Lower panel, RFP direct fluorescence microscopy on immortalized DMD myoblasts and on primary hMSCs transduced with Ad.ΔE1.TALEN-LS1.F50 or with Ad.ΔE1.TALEN-RS1.F50 at an MOI of 12 HTU/cell or co-transduced with a 1:1 mixture of Ad.ΔE1.TALEN-LS1.F50 and Ad.ΔE1.TALEN-RS1.F50 at a total MOI of 24 HTU/cell. The fluorescence microscopy images were acquired at 48 h post-infection. (B) HA tag-specific immunofluorescence microscopy on HeLa cells mock-transduced or transduced with Ad.ΔE1.TALEN-LS1.F50 or with Ad.ΔE1.TALEN-RS1.F50 at an MOI of 3 HTU/cell. The direct fluorescence microscopy and the immunofluorescence microscopy were carried out at 48 and 72 h post-infection, respectively. (C) HA tag-directed western blot analysis of protein lysates derived from HeLa cell cultures incubated for 72 h with Ad.ΔE1.TALEN-LS1.F50 or with Ad.ΔE1.TALEN-RS1.F50. The MOIs deployed are indicated.CC BY-NC · PubMed Central
Figure 4. Targeted disruption of the chromosomal AAVS1 locus. (A) Schematic representation of the Surveyor mutation detection assay used to probe TALEN activity in human cells. Assembly of the TALEN pair at the bipartite target sequence results in local DSB formation. The error-prone NHEJ DNA repair pathway links the broken chromosomal ends introducing in the process small insertions and deletions (indels) at the junction (gray boxes). PCR on chromosomal DNA with primers framing the target site yields a mixture of amplicons representing the heterogeneous population of mutated sequences and non-modified alleles. Denaturation and re-annealing of this mixture results in DNA species with internal base pairs that are mismatched. The SNS enzyme, by preferentially recognizing and cleaving at DNA sequences with such mismatched base pairs, yields low-molecular-weight DNA fragments (open arrowheads) that can be resolved from undigested DNA (solid arrowheads) through conventional agarose gel electrophoreses. Parallel samples not treated with SNS (−) served as a negative control. (B) TALEN activity at AAVS1. Upper panel, Surveyor assay on chromosomal DNA isolated from HeLa cells not exposed (mock) or exposed to Ad.ΔE1.TALEN-LS1.F50 or to Ad.ΔE1.TALEN-RS1.F50 at a high and a low dose (i.e. 6 and 2 HTU/cell, respectively). Lower panels, Surveyor assay on chromosomal DNA extracted from HeLa cells and DMD myoblasts (left and right panels, respectively). HeLa cells were mock-transduced (−) or were co-transduced with 6 HTU/cell of Ad.ΔE1.TALEN-LS1.F50 and 6 HTU/cell of Ad.ΔE1.TALEN-RS1.F50 (+). Human myoblasts were mock-transduced (−) or were co-transduced with 12 HTU/cell of Ad.ΔE1.TALEN-LS1.F50 and 12 HTU/cell of Ad.ΔE1.TALEN-RS1.F50 (+). Solid and open arrowheads indicate the positions of undigested and SNS-digested DNA molecules, respectively. White numerals correspond to the percentage of target site cleavage. (C) Dose-response of TALEN activity. Surveyor assay on cellular DNA from HeLa cells, DMD myoblasts and hMSCs untreated or treated with different doses of 1:1 mixtures of Ad.ΔE1.TALEN-LS1.F50 and Ad.ΔE1.TALEN-RS1.F50. In these dose-response co-transduction experiments, the total amounts of vector applied on HeLa cells were 12, 4, 1.3, 0.4 and 0.15 HTU/cell, whereas on DMD myoblasts and hMSCs, HTU/cell were 24, 8, 2.7, 1.0 and 0.3. Solid and open arrowheads indicate the positions of undigested and SNS-digested DNA molecules, respectively. White numerals correspond to the percentage of target site cleavage. (D) Sequence analysis. DNA sequencing of cloned AAVS1-specific amplicons resulting from PCR amplifications on genomic DNA isolated from hMSCs co-transduced with Ad.ΔE1.TALEN-LS1.F50 and Ad.ΔE1.TALEN-RS1.F50 at 12 HTU/cell each. The presence of indels in 12 of 20 clones, ‘footprint’ for NHEJ processing of DSBs, demonstrates at the nucleotide level the TALEN-mediated cleavage of the chromosomal AAVS1 target site.
Figure 4. Targeted disruption of the chromosomal AAVS1 locus. (A) Schematic representation of the Surveyor mutation detection assay used to probe TALEN activity in human cells. Assembly of the TALEN pair at the bipartite target sequence results in local DSB formation. The error-prone NHEJ DNA repair pathway links the broken chromosomal ends introducing in the process small insertions and deletions (indels) at the junction (gray boxes). PCR on chromosomal DNA with primers framing the target site yields a mixture of amplicons representing the heterogeneous population of mutated sequences and non-modified alleles. Denaturation and re-annealing of this mixture results in DNA species with internal base pairs that are mismatched. The SNS enzyme, by preferentially recognizing and cleaving at DNA sequences with such mismatched base pairs, yields low-molecular-weight DNA fragments (open arrowheads) that can be resolved from undigested DNA (solid arrowheads) through conventional agarose gel electrophoreses. Parallel samples not treated with SNS (−) served as a negative control. (B) TALEN activity at AAVS1. Upper panel, Surveyor assay on chromosomal DNA isolated from HeLa cells not exposed (mock) or exposed to Ad.ΔE1.TALEN-LS1.F50 or to Ad.ΔE1.TALEN-RS1.F50 at a high and a low dose (i.e. 6 and 2 HTU/cell, respectively). Lower panels, Surveyor assay on chromosomal DNA extracted from HeLa cells and DMD myoblasts (left and right panels, respectively). HeLa cells were mock-transduced (−) or were co-transduced with 6 HTU/cell of Ad.ΔE1.TALEN-LS1.F50 and 6 HTU/cell of Ad.ΔE1.TALEN-RS1.F50 (+). Human myoblasts were mock-transduced (−) or were co-transduced with 12 HTU/cell of Ad.ΔE1.TALEN-LS1.F50 and 12 HTU/cell of Ad.ΔE1.TALEN-RS1.F50 (+). Solid and open arrowheads indicate the positions of undigested and SNS-digested DNA molecules, respectively. White numerals correspond to the percentage of target site cleavage. (C) Dose-response of TALEN activity. Surveyor assay on cellular DNA from HeLa cells, DMD myoblasts and hMSCs untreated or treated with different doses of 1:1 mixtures of Ad.ΔE1.TALEN-LS1.F50 and Ad.ΔE1.TALEN-RS1.F50. In these dose-response co-transduction experiments, the total amounts of vector applied on HeLa cells were 12, 4, 1.3, 0.4 and 0.15 HTU/cell, whereas on DMD myoblasts and hMSCs, HTU/cell were 24, 8, 2.7, 1.0 and 0.3. Solid and open arrowheads indicate the positions of undigested and SNS-digested DNA molecules, respectively. White numerals correspond to the percentage of target site cleavage. (D) Sequence analysis. DNA sequencing of cloned AAVS1-specific amplicons resulting from PCR amplifications on genomic DNA isolated from hMSCs co-transduced with Ad.ΔE1.TALEN-LS1.F50 and Ad.ΔE1.TALEN-RS1.F50 at 12 HTU/cell each. The presence of indels in 12 of 20 clones, ‘footprint’ for NHEJ processing of DSBs, demonstrates at the nucleotide level the TALEN-mediated cleavage of the chromosomal AAVS1 target site.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 62 references

Research works printed but not linked: 1

  1. Coffin, 1997, Retroviruses

Cited by

See all 312

Metadata

Authors
Holkers, M., Maggio, I., Liu, J., Janssen, J. M., Miselli, F., Mussolino, C., Recchia, A., Cathomen, T., & Gonçalves, M. A. F. V.
Affiliations
University of Modena and Reggio Emilia (IT)
Corresponding author
Gonçalves, Manuel A. F. V.
Venue
Nucleic Acids Research
Published
2012-12-26
Volume
41
Issue
5
Pages
e63-e63
ISSN
  • 0305-1048 (ISSN-L)
  • 1362-4962
OpenAlex
W2090787765
Cited by
312
References
62
Citations by year
2026: 5 · 2025: 13 · 2024: 14 · 2023: 9 · 2022: 10 · 2021: 17 · 2020: 17 · 2019: 16 · 2018: 23 · 2017: 33 · 2016: 42 · 2015: 47 · 2014: 44 · 2013: 21
FWCI
21.52
Type
journal article
Language
en
Open access
Locations
  • Nucleic Acids Research (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
Funders
  • European Commission (222878)
  • Universiteit Leiden
  • Prinses Beatrix Spierfonds (W.OR11–18)
  • Leids Universitair Medisch Centrum
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
TALE nucleases, adenoviral vector, lentiviral vectors, HIV-1-based vectors, AAVS1 safe harbor, genome editing, DNA double-strand breaks, primary human cells
MeSH terms
Adenoviridae, Bacterial Proteins, Chromosomes, Human, Deoxyribonucleases, Genetic Vectors, HeLa Cells, Humans, Transduction, Genetic, HIV-1, DNA Breaks, Double-Stranded, Genetic Loci, HEK293 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells. https://app.cochat.ai/papers/10.1093/nar/gks1446
The paper
Holkers, M., Maggio, I., Liu, J., Janssen, J. M., Miselli, F., Mussolino, C., Recchia, A., Cathomen, T., & Gonçalves, M. A. F. V. (2013). Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells. Nucleic Acids Research. https://doi.org/10.1093/nar/gks1446

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.